TEVATeva Pharmaceutical Industries Limited

$37B

Q4 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$4.2B-5.1% YoY

Gross Profit

$2.1B50.1% margin

Operating Income

-$29M-0.7% margin

Net Income

-$217M-5.1% margin

EPS (Diluted)

$-0.19

QoQ Revenue Growth

-2.4%

Cash Flow

Operating Cash Flow

$575M

Free Cash Flow

$446M

Stock-Based Comp.

$34M

Balance Sheet

Total Assets

$39.3B

Total Liabilities

$33.6B

Stockholders' Equity

$5.4B

Cash & Equivalents

$3.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4.2B	$4.5B	-5.1%
Gross Profit	$2.1B	$2.4B	-12.3%
Operating Income	-$29M	$756M	-103.8%
Net Income	-$217M	$463M	-146.9%

Revenue Segments

Product

$7.0B87%

Distribution Service

$804M10%

Product and Service, Other

$157M2%

License

$92M1%

Geographic Segments

North America Segment

$3.7B49%

Europe Segment

$2.6B35%

International Markets

$1.3B17%

TEVA Q4 2024 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena